Medical management of gastrointestinal neuroendocrine tumors

Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):219-224. doi: 10.1097/MED.0000000000000711.

Abstract

Purpose of review: To summarize the recent developments in the medical treatment of gastrointestinal neuroendocrine neoplasms.

Recent findings: The medical management of gastrointestinal neuroendocrine tumors (GI-NETs) continues to evolve with advances in the management of symptoms related to hormone hypersecretion and therapeutic control of disease progression. Systemic therapy options include somatostatin analogs (SSAs), radiolabeled SSAs, molecularly targeted agents, and cytotoxic therapy. Recent progress has focused on new targeted therapies, the sequencing of therapy and the role of immunotherapy.

Summary: This review will focus on treatment of GI-NETs and highlight new developments published over the last year.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Disease Progression
  • Gastrointestinal Neoplasms* / drug therapy
  • Humans
  • Neuroendocrine Tumors* / drug therapy
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms* / drug therapy
  • Somatostatin / therapeutic use

Substances

  • Antineoplastic Agents
  • Somatostatin